Two companies have joined forces to investigate the potential for palbociclib, marketed by Pfizer (NYSE: PFE) as Ibrance, to be used as an Alzheimer’s disease drug.
China Resources Pharmaceutical Group (CR Pharmaceutical), the third-largest pharmaceutical distributor in the country, will work with Hong Kong’s Nano and Advanced Materials Institute (NAMI) on the project.
The collaboration seeks to combine NAMI’s nanotechnology expertise with CR’s manufacturing strengths. The focus is on optimizing the delivery of palbociclib, originally developed for advanced breast cancer and approved in 2015. The drug’s patent is scheduled to expire in 2027.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze